Of clinical significance, You et al. identified hsa-miR-363-3p as a master regulator of SQLE in pancreatic adenocarcinoma (PADD), with its tumor-suppressive effects extending beyond metabolic reprogramming to modulate immune checkpoint expression (PD-1/CTLA-4) and reshape the tumor microenvironment [59]. This evidence concerns the gene CTLA4 and neoplasm.